This edition is your shortcut to what’s shaping early-phase research across the globe. From regional momentum to regulatory shifts, here’s how to stay ahead of the curve: Navigate ethics approvals and fast-start trials in Australia.
first-in-human · FIH · clinical trial · regulatory · gene therapy
bioaccess® | Global Trial Accelerators™ | Fast-Tracking First-in-Human Trials, Anywhere
This edition is your shortcut to what’s shaping early-phase research across the globe. From regional momentum to regulatory shifts, here’s how to stay ahead of the curve:
Let’s get you where research is going—scroll down to begin.
Navigating early-phase medical device studies across Latin America requires more than just regulatory knowledge — it demands a regionally tailored, end-to-end operational strategy. From regulatory planning and site selection to bilingual documentation and patient access, a specialized early-phase CRO approach makes the difference between delays and first-patient-in success.
With clinical infrastructure maturing across Latin America, sponsors are now executing early-stage studies faster, more cost-effectively, and with broader patient access than ever before.
Despite advances in trial technology and planning, many sponsors still struggle with feasibility execution — often due to rigid protocols, outdated site assumptions, and exclusion of on-the-ground perspectives. The real cost? Delays, poor enrollment, and avoidable amendments.
Feasibility should be more than a spreadsheet exercise. In emerging markets like Latin America, localized insights, early investigator engagement, and language-aware outreach can make or break study success — especially for first-in-human and proof-of-concept trials.
Design flexibility and real-world site input aren’t just nice to have — they’re essential if you’re looking to fast-track activation and minimize risk.
Read the source at clinicalleader.com
Australia has approved a Phase I study of a novel small molecule targeting lung cancer, reinforcing its status as a prime destination for early-phase trials. With a streamlined ethics review process and robust clinical infrastructure, the country is increasingly favored by sponsors aiming for rapid FIH and dose-escalation studies.
Early-phase Medtech and Biopharma innovators benefit from English-language alignment, global regulatory credibility, and attractive R&D incentives — making Australia a smart complement to Latin America in multinational feasibility planning.
Read the source at biotechdispatch.com.au
Does Your Company Need Accelerated First-in-Human Clinical Trial Results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult
A next-generation guidewire designed to simplify transcatheter aortic valve replacement (TAVR) procedures has received FDA approval, underscoring how engineering precision is redefining structural heart innovation. The system aims to improve device navigation and reduce risk during complex valve interventions.
Early-phase teams in U.S. regulatory anchoring plus U.S. and Latin America execution should take note of how downstream innovation informs protocol design, especially in high-tech, anatomy-sensitive indications.
Read the source at medicaldevice-network.com
A novel gene therapy candidate for retinitis pigmentosa has demonstrated encouraging safety and early efficacy data in a first-in-human study, marking a pivotal step forward in the race to address inherited retinal diseases through precision medicine.
As gene therapies continue moving into early-phase trials, the ability to design lean, targeted protocols is becoming critical. These early signals guide regulatory planning, risk mitigation, and regional trial strategy for Biopharma teams looking to enter rare or high-impact therapeutic areas.
Read the source at clinicaltrialsarena.com
The FDA is expected to intensify its focus on cybersecurity requirements for connected medical devices by 2026, signaling a shift toward more proactive regulation of digital risk. As Medtech innovation increasingly relies on software and connectivity, regulators are aiming to ensure that patient safety extends beyond physical device performance.
For early-phase developers, especially those working on digital or data-integrated technologies, this signals a growing need to bake cybersecurity into design from the outset. Anticipating regulatory expectations early can streamline global approval strategies and avoid costly redesigns down the line.
Read the source at medicaldevice-network.com
← All Global Trial Accelerators editions · Contact bioaccess®